Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-SC01 for Perianal Fistulas in Crohn's Disease
NCT05626023Phase 2Completed
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TH-SC01 in perianal fistula and Crohn's disease, sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoints: Severity and incidence of adverse events at 28 days, Dose-limiting toxicity at 84 days and 1 more. Started Jan 2022; status: completed.
02
Drugs
TH-SC01
03
Conditions
perianal fistulaCrohn's disease
Beyond the preview
Go deeper on NCT05626023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626023.